Swedish biopharmaceutical company Alzinova AB (Nasdaq First North Growth Market:ALZ) said on Wednesday that it has initiated a research collaboration with Amsterdam University Medical Center (UMC) to develop a blood-based diagnostic test for Alzheimer's disease.

The collaboration focuses on measuring naturally occurring antibodies against toxic amyloid-beta oligomers in healthy individuals, leveraging Alzinova's proprietary Aβ42CC oligomer technology (ALZ-101 antigen).

According to Alzinova, the objective is to establish an assay with clinically relevant sensitivity and specificity that could enable a commercially viable diagnostic with a shorter development timeline than traditional therapeutics.

The initiative builds on growing interest from international diagnostics companies, supported by data indicating higher antibody levels in healthy elderly individuals compared with younger individuals and Alzheimer's patients. This suggests reduced antibody levels may serve as a prognostic biomarker for identifying individuals at increased risk before symptoms emerge, supporting opportunities within the expanding Alzheimer's diagnostics market.

The collaboration is expected to run for approximately 3 to 4 months, with initial results anticipated in the third quarter of 2026 and funded within Alzinova's existing budget.

This work is independent of the ongoing clinical development of ALZ-101 but is positioned to create potential long-term synergies between diagnostics and therapy within a disease-modifying platform.